Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 825-837

  Gelbert, Lawrence M ^a,d   Cai, Shufen ^a   Lin, Xi ^a   Sanchez Martinez, Concepcion ^b   Prado, Miriam Del ^b   Lallena, Maria Jose ^b   Torres, Raquel ^b   Ajamie, Rose T ^a   Wishart, Graham N ^a   Flack, Robert Steven ^c   Neubauer, Blake Lee ^c   Young, Jamie ^c   Chan, Edward M ^a   Iversen, Philip ^a   Cronier, Damien ^a   Kreklau, Emiko ^a   De Dios, Alfonso ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AND COMPANY   (Spain)

^c Covance Laboratories ^*  (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cdk4 6 inhibitor; Cell cycle; Combination therapy; In vivo antitumor activity; Kinase inhibitor; LY2835219

Indexed keywords

5-(4-ETHYLPIPERAZIN-1-YLMETHYL)PYRIDIN-2-YL)-(5-FLUORO-4-(7-FLUORO-3-ISOPROPYL-2-METHYL-3H-BENZOIMIDAZOL-5-YL)PYRIMIDIN-2-YL)AMINE; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DEOXYCYTIDINE; GEMCITABINE; PROTEIN KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; METABOLISM; MOUSE; NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR VOLUME;

AMINOPYRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RETINOBLASTOMA PROTEIN; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930696140     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0120-7     Document Type: Article

References (53)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
2. Pardee AB (1974) A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 71:1286-1290
3. Blagosklonny MV, Pardee AB (2002) The restriction point of the cell cycle. Cell Cycle 1:103-110
4. Ortega S, Malumbres M, Barbacid M (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602:73-87
5. Dyson N (1998) The regulation of E2F by pRB-family proteins. Genes Dev 12:2245-2262
6. Gladden AB, Diehl JA(2005) Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem 96:906-913
7. Harbour JW, Luo RX, Santi AD, Postigo AA, Dean DC (1999) Cdk Phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98:859-869
8. Lundberg AS, Weinberg RA (1998) Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18:753-761
9. Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M et al (2001) Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 21:4684-4699
10. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM et al (2011) A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20:620-634
11. Fagan R, Flint KJ, Jones N (1994) Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19 kDa protein. Cell 78:799-811
12. Donnellan R, Chetty R (1998) Cyclin D1 and human neoplasia. Mol Pathol 51:1-7
13. Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A (2005) Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23:6364-6369
14. Wang L, Wang J, Blaser BW, Duchemin A-M, Kusewitt DF, Liu T et al (2007) Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 110:2075-2083
15. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL et al (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715-721
16. Reifenberger G, Reifenberger J, Ichimura K, Peter CV (1995) Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Cancer Res 55:731-734
17. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T et al (2011) Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 17:1924-1934
18. Chin L (2003) The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 3:559-570
19. Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ et al (1990) Frequent inactivation of the retinoblastoma antioncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci U S A 87:2775-2779
20. Ruas M, Peters G (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378:F115-F177
21. Hughes A (2006) CDK inhibitors in 3D: Problems with the drugs, their development plans or their linkage to disease? Gene Ther Mol Biol 10:41-54
22. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427-1438
23. Oelgeschläger T (2002) Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 190:160-169
24. Kitagawa M, Higashi H, Jung HK, Suzuki-Takahashi I, Ikeda M, Tamai K et al (1996) The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 15:7060-7069
25. Goswami PC, Roti Roti JL, Hunt CR (1996) The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation. Mol Cell Biol 16:1500-1508
26. Goto H, Tomono Y, Ajiro K, Kosako H, Fujita M, Sakurai M et al (1999) Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 274:25543-25549
27. Musgrove EA, Lilischkis R, Cornish AL, Lee CS, Setlur V, Seshadri R et al (1995) Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer 63:584-591
28. Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK et al (2002) Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 277:44376-44384
29. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10:130-137
30. Deep G, Agarwal R (2008) New combination therapies with cellcycle agents. Curr Opin Investig Drugs 9:591-604
31. Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Houghton JA, Rutherford PG et al (1996) Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Investig New Drugs 14:243-247
32. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222-231
33. Malumbres M, Barbacid M (2006) Is Cyclin D1-CDK4 kinase a bona fide cancer target? Cancer Cell 9:2-4
34. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783
35. Guha M (2012) Cyclin-dependent kinase inhibitors move into Phase III. Nat Rev Drug Discov 11:892-894
36. Lin X, Gelbert L, Chu S, Medina D, Garcia-Paredes C, De Dios A (2007) High throughput multiplexing phospho retinoblastoma tumor suppressor protein (Rb) and cell cycle analysis using acumen technology. In: Proceedings of the AACR Annual Meeting; Apr 15; Los Angeles, CA. Abstract nr 4372
37. Tate SC, Cai S, Ajamie RT, Burke T, Beckmann RP, Chan EM, et al (2014)Semi-mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Tumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts. Clin Can Res doi:10.1158/1078-0432.CCR-13-2846
38. Shapiro G, Rosen LS, Tolcher, AW, Goldman JW, Gandhi L, Papadopoulos KP, et al A first-in-human phase I study o fthe CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol 31, 2013 (Suppl; abstr 2500).
39. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer [abstract]. AACR 2014 Apr 7; Abstr CT-232.
40. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M et al (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105:1759-1767
41. Kim KT, Levis M, Small D (2006) Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol 134:500-509
42. de Vos S, Krug U, Hofmann WK, Pinkus GS, Swerdlow SH, Wachsman W et al (2003) Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol 12:35-43
43. Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E et al (2002) Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 119:905-915
44. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130
45. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A et al (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:4731-4737
46. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64:3761-3766
47. Barton KL, Misuraca K, Cordero F, Dobrikova E, Min HD, Gromeier M et al (2013) PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One 8:e77639
48. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G et al (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18:63-73
49. Dempsey JA, Chan EM, Burke TF, Beckmann RP (2013) LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer. Cancer Res; 73(8Suppl): LB-122.
50. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
51. Steeg PS, Camphausen KA, Smith QR (2011) Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 11:352-363
52. Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29:533
53. Pelletier EM, Shim B, Goodman S, Amonkar MM (2008) Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat 108:297-305